Navigation Links
MGB Biopharma to Present at Bio-Europe 2013
Date:11/4/2013

GLASGOW, Scotland, November 4, 2013 /PRNewswire/ --

MGB Biopharma, a biopharmaceutical company developing truly novel anti-infectives, announces today that CEO Dr Miroslav Ravic will present at  Bio-Europe 2013  in Vienna, Austria (4-6 November). Details of the presentation on 6 November are listed below.  

Dr Ravic will highlight MGB Biopharma's recent rapid progress in developing a truly novel class of anti-infectives. The Company's lead candidate MGB-BP-3 is an antibacterial active against a broad range of multi-resistant Gram-positive pathogens. The Company has completed preclinical development of an oral formulation that is ready to enter the clinic for Clostridium difficile. In addition, MGB Biopharma is developing an intravenous formulation of MGB-BP-3 for hospital acquired Gram-positive infections and this is expected to be IND-ready by the end of 2014.

MGB-based anti-infectives have the potential to deliver significant advantages over current approaches including broad, bactericidal activity against multi-resistant Gram-positive and Gram-negative pathogens. The platform also promises to deliver compounds that are active against certain viruses, fungi and parasites. MGB's anti-infectives are based on its minor groove binder (MGB) technology platform.

Dr Miroslav Ravic, CEO of MGB Biopharma, said: "Antimicrobial resistance is clearly a major global public health concern. Yet, the lack of truly novel agents, even among late stage candidates, means that, as an industry, we are ill equipped to tackle this problem. We believe that MGB's truly novel minor groove binder technology platform, could for the first time in a more than a decade, provide novel agents that offer a real breakthrough in addressing antimicrobial resistance. In particular our lead candidate MGB-BP-3 has shown significant antibacterial activity against a range of Gram positive pathogens and we expect to announce further progress with our on-going programs with MGB-BP-3 in the coming months."

Details of the presentation are as follow:

Title: Infectious Diseases Presentation stream: MGB Biopharma Limited

Time: 10.15am

Location: Level 1, Schubert 4

Venue: Messe Wien Exhibition and Congress Center

About MGB Biopharma

MGB Biopharma is developing a truly novel class of anti-infectives. MGB's lead candidate, MGB-BP-3, is a broad spectrum antibacterial which is active against key multi-resistant Gram positive pathogens. The Company has developed an oral formulation of MGB-BP-3 for Clostridium difficile that is ready to enter the clinic, while an IV formulation for a range of Gram positive infections is in late-stage preclinical development.

MGB's anti-infective drug development capabilities are driven by its broad anti-infective platform, which has the potential to generate truly novel compounds active against other infectious diseases such as Gram negative pathogens as well parasites and fungi.

MGB's anti-infectives are based on minor groove binders (MGBs). Minor groove binders have a new mode of action that offers significant advantages over existing anti-infectives, such as being more bactericidal and active against a broad range of drug-resistant bacteria.

MGB has close links with the University of Strathclyde, with exclusive worldwide licence rights to Strathclyde's MGB patents for all fields expect anticancer. The Company intends to work with partners to fully capitalize on the multiple value creating opportunities offered by its broad and novel anti-infectives platform.

The Company was founded in 2010 and is headquartered in Glasgow, Scotland. It is backed by Scotland's investors including Archangel Informal Investment, Barwell, TriCapital and Scottish Co-Investment Fund. For more information please visit http://www.mgb-biopharma.com.

For further information, please contact:

MGB Biopharma
Gavin Clark, Chief Business Officer
gclark@mgb-biopharma.com
+44(0)7867-504-793

Citigate Dewe Rogerson
David Dible/Sita Shah
sita.shah@citigatedr.co.uk
+44(0)20-7282-1052


'/>"/>
SOURCE MGB Biopharma
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
2. PDL BioPharma to Announce Third Quarter 2013 Financial Results on November 6, 2013
3. Regeneron Named Top Employer in the Global Biopharmaceutical Industry for the Second Year in a Row
4. Bright Future Ahead for Biopharmaceutical Contract Manufacturing, Says Frost & Sullivan
5. Enteris BioPharma and Nordic BioSciences KeyBioScience Enter Strategic Licensing Agreement to Develop Metabolic Peptides Using Enteris Proprietary Oral Drug Delivery and Manufacturing Platform
6. CDISC and TransCelerate BioPharma Inc. Announce Landmark Asthma Data Standard Released for Public Review
7. Benu BioVentures to Finance Early Biopharmaceutical Clinical Development
8. Therapure Biopharma Inc. wins a 2013 CMO Leadership Award in All 5 Categories: Quality, Reliability, Innovation, Productivity and Regulatory
9. Recently Patented Technology Poised To Disrupt The Plasma Biopharmaceutical Market
10. Life Cycle Management of Biopharmaceuticals, New Life Science Webinar Hosted by Xtalks
11. KBI Biopharma Selects Freeslate’s Biologics Formulation System for Early and Late Stage Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... They call it the “hairy ... a depiction of a system of linkages and connections so complex and dense ... of computer science at Worcester Polytechnic Institute (WPI) and director of the university’s ...
(Date:10/12/2017)... ... October 12, 2017 , ... DuPont Pioneer and ... they have entered into a multiyear collaboration to identify and characterize novel CRISPR-Cas ... tools for gene editing across all applications. , Under the terms of the ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS ... the addition of its newest module, US Hemostats & Sealants. , SmartTRAK’s US ... absorbable hemostats, fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... genomics analysis platform specifically designed for life science researchers to analyze and ... researcher Rosalind Franklin, who made a major contribution to the discovery of ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017  On April 6-7, 2017, ... the Genome hackathon at Microsoft,s headquarters in ... competition will focus on developing health and wellness apps ... Hack the Genome is the first hackathon ... The world,s largest companies in the genomics, tech and ...
(Date:3/28/2017)... March 28, 2017 The report ... (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, VMS), ... - Global Forecast to 2022", published by MarketsandMarkets, the ... and is projected to reach USD 75.64 Billion by ... 2022. The base year considered for the study is ...
(Date:3/23/2017)... , March 23, 2017 The report "Gesture Recognition ... Biometric), Industry, and Geography - Global Forecast to 2022", published by MarketsandMarkets, the ... a CAGR of 29.63% between 2017 and 2022. ... ... ...
Breaking Biology News(10 mins):